Bioversys Ag · SIX:BIOV
Bioversys — FY2025 Earnings Presentation
27 slides from Bioversys's earnings presentation, Mar 18, 2026
Slide 1: Saving Lives in Resistant Times - Earnings Call March 2026
Most Compelling Investment Opportunity in AMR space January 2023 SAVING LIVES IN RESISTANT TIMES Earnings call March 18, 2026 March 2026| BioVersys – Proprietary Material MARCH 2026 EARNINGS CALL BIOVERSYS - PROPRIETARY MATERIAL 1
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation (the “Presentation”) has been prepared by BioVersys AG (“the Company” and together with its subsidiaries, “we”, “us” or the “Group”) solely for informational purposes and should be read in conjunction with the press release that was issued by the Company
Slide 3: Today's Presenters
TODAY’S PRESENTERS Marc Gitzinger Hernan Levett Glenn E. Dale Daniel Ritz Chief Executive Officer, Chief Financial Officer Chief Development Officer Chief Scientific Officer Founder 30+ years finance and management 30+ years research and development 30+ years research and development 15+ years biote
Slide 4: Innovative, Diverse and De-risked Pipeline
INNOVATIVE, DIVERSE AND DE-RISKED PIPELINE Next-Generation Antimicrobial Drugs, Two Proprietary Platforms Expected Key Commercial Program Indication R&D/Preclinical Phase 1 Phase 2 Phase 3 Potential Catalyst Rights Hospital infections $800m in Expected BV100 Phase 3 trial (RIV-TARGET) FPFV: April 20
Slide 5: FY 2025 Achievements
FY 2025 Achievements Strong execution of strategy: progressed pipeline and entered new partnerships Clinical Trials BV100 in VABP/HABP due to CRAB ✓ Global Phase 3 trial (RIV-TARGET) initiated, on track to read-out by end 2027 ✓ US FDA green lights IND ✓ Phase 1 trial in China initiated – Aiming to
Slide 6: FY 2025 Achievements
FY 2025 Achievements Strong execution of strategy: progressed pipeline and entered new partnerships Corporate New partnerships provide validation and non-dilutive funding Global research collaboration with Shionogi for BV500: • CHF 5 million in upfront and near-term payment • Up to CHF 479m in devel
Slide 7: Good Progress Made with Antibiotics Incentives Piloted Across Major Markets (G7)
Good Progress Made with Antibiotics Incentives Piloted Across Major Markets (G7) Programs Already Running Bipartisan Bill in Congress EU Pharma legislation Ongoing Implementing PASTEUR ACT Pioneering incentive implemented by UK. $750m-3bn over 10 years per new antibiotic1,2 EU implements Transferrab
Slide 8: BV100: Severe hospital infections caused by carbapenem resistant Acinetobacter baumannii
BV100: Severe hospital infections caused by carbapenem resistant Acinetobacter baumannii
Slide 9: BV100 development strategy and next steps
BV100 development strategy and next steps Phase 3 on track to read-out by end 2027 in HABP/VABP CRAB infections As a reminder, during 2025 the BV100 Phase 2 clinical trial delivered encouraging results: • Significantly reduced all-cause mortality in VABP (from 60% to 28.5%) randomized to best availa
Slide 10: Phase 3 RIV-TARGET
PHASE 3 RIV-TARGET Dual-Trial Strategy for Approval & Adoption GOAL: Demonstrate non-inferiority (with test for superiority) vs. Colistin based therapy for regulatory submissions initially in the US, Europe and China BV100 + low- dose PolB Key Endpoints Part A 248 evaluable Patients ∼ 300 Patients m
Slide 11: Phase 2b RIV-CARE
PHASE 2B RIV-CARE Dual-Trial Strategy for Approval & Adoption GOAL: Generate 'real-world' data for physician adoption and improved initial commercial uptake BV100 + low-dose PolB cef/avi background Part A Study conducted in 90 Patients ∼ 100 Patients BV100 + low-dose PolB collaboration with 1:1:1 wi
Slide 12: BV100 Outlook
BV100 OUTLOOK All focus on pivotal clinical trial execution • Phase 1 bridging study in China to be completed • RIV-TARGET Phase 3 FPFV anticipated within the next weeks • Onboarding China into Phase 3 trial in H2 2026 • Drug safety monitoring board updates in late 2026 • Guidance remains for last p
Slide 13: Alpibectir: Pulmonary and meningeal Tuberculosis
Alpibectir: Pulmonary and meningeal Tuberculosis
Slide 14: Alpibectir Clinical Development
ALPIBECTIR CLINICAL DEVELOPMENT Identifying future high impact regimens for Tuberculosis patients • Robust Phase 2a POC data with alpibectir in combination with ethionamide (AlpE) in pulmonary TB • Reported first patient first visit for the Phase 2 combination trial in pulmonary TB in Q1 2025 (ENABL
Slide 15: Ongoing Clinical Study in Pulmonary TB
ONGOING CLINICAL STUDY IN PULMONARY TB Phase 2 combination study (run by GSK in UNITE4TB) • A Phase 2a Randomized, Open-label Trial to Evaluate the EBA, • A multiple-arm, multiple-stage (MAMS), phase 2B/C, open- Safety, Tolerability, and Dose-Response of oral Alpibectir in label, randomized, control
Slide 16: Alpibectir Phase 2 TB Meningitis Study
ALPIBECTIR PHASE 2 TB MENINGITIS STUDY • A multicenter, open-label, randomized, active-controlled, Phase 2 study to evaluate the plasma and CSF pharmacokinetics, safety and exploratory efficacy of ethionamide in combination with alpibectir (AlpE) in adults and adolescent patients with newly diagnose
Slide 17: BV500: NTM for CF and COPD
SHIONOGI VERSYS BV500: NTM for CF and COPD
Slide 18: BV500 an NTM Asset Partnered with Shionogi
BV500 AN NTM ASSET PARTNERED WITH SHIONOGI • Global research collaboration started in 3Q25 with exclusive option to license • Upfront and near-term payments of CHF 5 million • Up to CHF 479 million in regulatory, development and sales milestones upon license option • Royalties on sales • Leveraging
Slide 19: Financial Highlights
VERSYS Financial Highlights
Slide 20: Full Year 2025 Highlights
FULL YEAR 2025 HIGHLIGHTS • Cash and Cash equivalents at the end of December 31, 2025 amounted to CHF 82.5 million. • Financial discipline: Capital allocated primarily to R&D activities (approx. 71% of total costs) and maintaining a lean organization of 33 FTEs led to an operational loss of CHF 21.8
Slide 21: Profit and Loss – December 31, 2025
PROFIT AND LOSS – DECEMBER 31, 2025 in CHF million (based on consolidated IFRS financial statements) Results Full Year 2025 Change vs Full Year 2024 3,3 2,1 -16,5 -3,6 0,3 -6,7 -1,9 -1,9 -21,8 -3,1 Operating R&D expenses G&A expenses Finance result Net loss for Operating R&D expenses G&A expenses Fi
Slide 22: Balance Sheet – December 31, 2025
BALANCE SHEET – DECEMBER 31, 2025 in CHF million (based on consolidated IFRS financial statements) Financial Position as of December 31, 2025 Change vs December 31, 2024 90,6 90,6 55,7 55,7 8,9 -0,8 49,1 7,3 21,9 59,8 89,9 55,5 0,8 0,2 Non- Current Total Equity Non- Current Total Non- Current Total
Slide 23: Cash Flow – December 31, 2025
CASH FLOW – DECEMBER 31, 2025 in CHF million (based on consolidated IFRS financial statements) Cash Flow 82,5 -0,5 72,6 26,6 -21,9 5,8 Cash and cash Cash flow from Cash flow from Cash flow from Exchange Cash and cash equivalents 31.12.2024 operating activities investing activities financing activiti
Slide 24: Guidance for 2026
GUIDANCE FOR 2026 • Operating Loss for the year 2026 expected to be in the range of CHF 40 to 45 million • Cash and cash equivalents at year end are estimated to be in the order of CHF 43 million • We expect the company’s operations to be funded into 2028 • Continue discussions with key institutions
Slide 25: Summary
Summary
Slide 26: Focused on Shareholder Value Creation
FOCUSED ON SHAREHOLDER VALUE CREATION Successful 2025 delivering on key catalysts and advancing into Phase 3 approval trial Achievements H1 2025 ✓ BV100 FDA IND green light and first country approvals for RIV-TARGET trial, RIV-CARE trial submitted in first countries ✓ RIV-CARE trial to be run in col
Slide 27: Q&A Contact information
Q&A Contact information: Website: www.bioversys.com IR mail: IR@bioversys.com